Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. is demonstrating a positive momentum in its test volume for EsoGuard, with a year-over-year growth of 2% in 3Q25, surpassing estimates with a total of 2,841 tests performed. The company's strategic efforts to expand coverage through Medicare and various private payer plans are expected to significantly boost revenue growth as commercialization of EsoGuard progresses. Additionally, a favorable outcome from the recent MolDX CAC meeting increases the likelihood of improved Medicare engagement, thus presenting a substantial upside potential for Lucid Diagnostics amidst its inherent risks.

Bears say

Lucid Diagnostics Inc. reported a pro forma net loss of $9.9 million for 3Q25, which slightly exceeded internal estimates and consensus expectations, indicating a continued struggle to achieve profitability. Revenue for the quarter also fell below consensus, with a noticeable decline in EsoGuard tests processed, reflecting challenges in adoption and effectiveness of marketing strategies. These performance metrics, combined with significant risks related to reimbursement, competition, and liquidity, lead to a concerning outlook for the company's future financial health.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.